Medtronic has led a $37 million investment in CoreMap, a startup developing a cardiac mapping platform designed to improve treatment for atrial fibrillation, or AFib.
The funding round, announced Wednesday, will accelerate CoreMap’s path to market. The company’s technology aims to help physicians pinpoint the specific cardiac sites driving complex arrhythmias, guiding more precise ablation procedures.
Mapping a path to better AFib treatment
AFib affects millions of people worldwide, increasing the risk of stroke and death. Ablation—using radiofrequency or pulsed field energy to destroy problematic tissue—can be effective, but success depends on accurately identifying the sources of the arrhythmia.
Current mapping systems, sold by companies like Abbott, Johnson & Johnson, and Medtronic, have limitations. CoreMap’s platform is designed to address those gaps, offering higher spatial resolution to detect closely spaced activations that existing devices might miss.
Medtronic, which already markets the Affera mapping and ablation system, sees potential in CoreMap’s approach. “CoreMap is addressing one of the critical unmet needs in AFib treatment with a differentiated technology platform and strong clinical support,” said Chris Eso, Medtronic’s global head of corporate and business development, M&A, and ventures.
CoreMap’s system isn’t the only new player in the space, but it arrives as the electrophysiology market undergoes rapid change. Pulsed field ablation (PFA) products, once dominated by Boston Scientific and Medtronic, now face competition from Abbott and J&J. The shift has pushed companies to refine their tools, particularly in mapping and precision targeting.
Related: Boston Scientific trims outlook again
The investment in CoreMap reflects a broader trend: established medtech firms are increasingly backing startups with complementary technologies. For Medtronic, the move could strengthen its position in a market where better mapping could mean better outcomes—and a competitive edge.
Clinical trials underway
CoreMap began enrolling patients in a clinical trial of its system in 2024. The FDA approved the study’s expansion into the U.S. in 2025, allowing the company to gather data on its platform’s safety and effectiveness.
The trial has three phases, with the final stage comparing CoreMap’s system to a control arm. Researchers will evaluate whether the technology can reliably identify AFib drivers and guide ablation therapy more effectively than existing methods.
The company’s work has already drawn government interest. In 2020, CoreMap received U.S. funding based on the potential of its technology to overcome the spatial resolution limitations of current devices. The $37 million Series C round builds on earlier investments, including a $10.5 million Series A in 2020 and a $23 million Series B in 2022.
If successful, CoreMap’s platform could change how physicians approach AFib treatment. For now, the focus remains on proving its value in clinical settings—and convincing a market already crowded with established players.
